DI CORPORATION

003160KOSPIMedical, precision and optical instruments

DI CORPORATION (003160, KOSPI) reported KRW 432bn revenue in 2025.

Broker research: target prices and ratings

2 reports from 2 firms between 2026-09-07 and 2026-10-13. One firm stated a target price: KRW 60,000.

Newest first. Ratings are as each firm stated them, translated into English. "Not stated" means the report carried no value — it is not a zero.

DateTarget priceRatingFirmAnalyst
KRW 60,000BuyDaishin SecuritiesNot stated
Not statedNot statediM SecuritiesNot stated

Report titles are not shown: the source lists them in Korean only, and we do not publish our own translation of another firm's headline.

This is a record of what brokers published, not investment advice. It is a sample of broker research — the reports our collection picked up, not every report written on this company — and the range and median describe that sample, not a market consensus. These are statistics, not a verdict.

Source: broker reports collected by SeoulMarkets from Naver Finance's research listing and from brokers' own websites, 2026-06-29 to 2026-10-28.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
20212271615248152Consolidated
20222311115275163Consolidated
202321562281161Consolidated
202421433320168Consolidated
20254323714374186Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
20217.3%6.7%61.3%10%
20224.8%6.6%59.5%9.3%
20232.9%0.9%57.5%1.2%
20241.4%1.3%52.5%1.7%
20258.4%3.1%49.7%7.3%

Revenue moved 90.8% between 2021 and 2025.

Net profit was positive in the 5 most recent consecutive years on file — every year we hold. Counted from the 5 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 883bn
Close priceKRW 31,200
Listed shares28,300,000
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

When it was founded

The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.

Incorporated

Who runs it

Registered representative directors — in Korea this is the office a CEO holds. Filed with the Financial Supervisory Service (DART). A Korean company can register more than one, and the title beside each name is the rank they carry inside the company.

NameTitleBoard seatYears in post
Park Won-ho (박원호)Representative Director (CEO), ChairmanInside director43 years
Cho Yun-hyeong (조윤형)Representative Director (CEO), Executive Vice PresidentInside director23 years

Roman spellings are ours, converted from the Korean filing. The person may spell their own name differently in English. The Korean name in brackets is what was filed.

Workforce — a side measure, not the main one

Employees (2025)171
Women21 (12.3%)
Average tenure9.7 years
Annual pay, menKRW 95,000,000
Annual pay, womenKRW 95,000,000
Pay ratio, women to men100%

Other companies in Medical, precision and optical instruments

102 listed companies file under this classification. Showing 12.

See the whole Medical, precision and optical instruments list →